Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm

Parkinsonism and Related Disorders

Volumn 13, Issue 8, 2007, Pages 505-508

  Ochudlo, Stanislaw ^a   Bryniarski, Piotr ^a   Opala, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Blepharospasm; Botulinum toxin type A; Depression; Quality of life

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; BLEPHAROSPASM; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIPLOPIA; DRUG DOSE REGIMEN; DYSTONIA; HUMAN; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; PTOSIS; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; SINGLE DRUG DOSE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; BLEPHAROSPASM; BOTULINUM TOXIN TYPE A; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 36048950559     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2007.03.006     Document Type: Article

References (5)

1. Muller J., Kemmler G., Wissel J., Schneider A., Voller B., Grossmann J., et al. Austrian Botulinum toxin and dystonia study group. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol 249 7 (2002) 842-846
2. Marchetti A., Magar R., Findley L., Larsen J.P., Pirtosek Z., Ruzicka E., et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 20 8 (2005) 937-944
3. Tucha O., Naumann M., Berg D., Alders G.L., and Lange K.W. Quality of life in patients with blepharospasm. Acta Neurol Scand 103 1 (2001) 49-52
4. Reimer J., Gilg K., Karow A., Esser J., and Franke G.H. Health-related quality of life in blepharospasm or hemifacial spasm. Acta Neurol Scand 111 1 (2005) 64-70
5. Costa P.G., Aoki L., Saraiva F.P., and Matayoshi S. Botulinum toxin in the treatment of facial dystonia: evaluation of its efficacy and patients' satisfaction along the treatment. Arq Bras Oftalmol 68 4 (2005) 471-474